MedPath

Cognition Therapeutics Price Target Increased by H.C. Wainwright

7 months ago1 min read
H.C. Wainwright has increased its price target for Cognition Therapeutics (CGTX) to $6 from $5, while keeping a Buy rating on the shares. This adjustment comes after the company announced positive top-line results from the Phase 2 SHIMMER trial of its leading candidate, CT1812, a sigma-2 receptor modulator, in patients with dementia with Lewy bodies. The firm has incorporated the dementia with Lewy bodies indication into its valuation assessment, assigning it a 30% likelihood of approval.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.